According to the most recent statement that Ironwood Pharmaceuticals, Inc. made with the Securities and Exchange Commission, the State of New Jersey Common Pension Fund D increased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 6.8% in the third quarter. The statement was made public by Ironwood Pharmaceuticals, Inc. During the period in question; the institutional investor purchased an additional 13,566 shares of stock in the biotechnology company. This brought the total number of shares owned by the investor to 213,014. Ironwood Pharmaceuticals was valued at $2,207,00 at the end of the most recent reporting period. The State of New Jersey Common Pension Fund D owned approximately 0.14% of the company.
Other major investors have followed suit and cut back on the number of IRWD shares they currently hold in their portfolios. The amount of $55,000 was contributed by Gladius Capital Management LP during the second quarter of 2018 toward acquiring a new investment in Ironwood Pharmaceuticals. Banque Cantonale Vaudoise made a new investment in Ironwood Pharmaceuticals during the second quarter by purchasing a new ownership interest for approximately $58,000. The transaction took place during the second quarter. During the second quarter, Captrust Financial Advisors made a staggering increase of 441.7% in the quantity of Ironwood Pharmaceuticals stock that it held. Captrust Financial Advisors now has 6,690 shares of stock in the biotechnology company after purchasing an additional 5,455 shares during the most recent quarter. The value of the biotechnology company’s 6,690 shares of stock is $77,000. During the first quarter, Lazard Asset Management LLC increased its stake in Ironwood Pharmaceuticals by investing approximately $78,000. This brought the total amount of Lazard’s investments in the company to approximately $120,000. Last but not least, during the first three months of 2018, Quantbot Technologies LP spent approximately $109,000 to acquire a new interest in Ironwood Pharmaceuticals. This was the company’s only investment.
Additional information regarding Ironwood Pharmaceuticals includes the fact that on January 5, the Chief Executive Officer of the company, Thomas A. Mccourt, sold 110,962 shares of the company’s stock. The average price paid for a share of stock was $12.07, and a total of $1,339,311.34 was transacted to purchase those shares. Following the transaction’s completion, the company’s CEO holds a total of 712,440 shares, each of which is currently estimated to be worth approximately $8,599,150.80. If you follow the link, which will take you to a legal file submitted to the SEC, you will have the opportunity to acquire additional information regarding the transaction. The total number of shares owned by the company’s insiders is 13.10%.
On Wednesday, NASDAQ: IRWD was trading at $11.41 per share. The price of the company’s shares has fluctuated between $11.89 and $11.39 on a moving average over the past fifty and two hundred days, respectively. The current price per share for the stock is $12.01, with a beta value of 0.96 and a market value of $1.75 billion. The current, quick, and debt-to-equity ratios all come in at the same number, which is 25.78. The debt-to-equity ratio is currently at 0.67. Ironwood Pharmaceuticals, Inc. hit an all-time low of $9.73 during the past year, while the company reached an all-time high of $12.95 during the same period.
On November 3, the most recent earnings report for Ironwood Pharmaceuticals (NASDAQ: IRWD) was made available to the general public. The biotechnology company announced earnings per share for the quarter of $0.28, which was $0.01 higher than the predictions made by the analysts as a consensus. Despite analysts’ predictions that the company would bring in $111.51 million in revenue during the quarter, the actual amount the business could bring in was only $108.64 million. In their financial statements, Ironwood Pharmaceuticals indicated that they had each